Six Minute Walking Test and Carbon Monoxide Diffusing Capacity for Non-small Cell Lung Cancer: Easy Performed Tests in Every Day Practice

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2012 Dec 4

PMID 23205280

Citations 4

Authors

Paul Zarogoulidis

Theodora Kerenidi

Haidong Huang

Theodoros Kontakiotis

Ourania Tremma

Konstantinos Porpodis

Anastasios Kalianos

Ageliki Rapti

Christoforos Foroulis

Athanasios Zissimopoulos

Nikolaos Courcoutsakis

Konstantinos Zarogoulidis

Affiliations

Soon will be listed here.

Abstract

Background: Several studies have demonstrated that reduced lung function is a significant risk factor for lung cancer and increased surgical risk in patients with operable stages of lung cancer. The aim of the study was to perform pulmonary function tests and investigate which is a favorable respiratory function test for overall survival between lung cancer stages.

Methods: Lung function tests were performed to lung cancer patients with non-small cell lung cancer of stage I, II, III and IV (241 patients in total). They had the last follow-up consecutively between December 2006 and July 2008. The staging was decided according to the sixth edition of TNM classification of NSCLC. The Forced Expiratory Volume in 1sec (FEV1), Forced Vital Capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) were measured according to American Thoracic Society/European Respiratory Society guidelines. The 6 Minute Walking Test (6MWT) was measured according to the American Thoracic Society.

Results: There was a significant association of the DLCO upon diagnosis and overall survival for stage II (P<0.007) and IV (P<0.003). Furthermore, there was a significant association between 6MWT and overall survival for stage III (P<0.001) and stage IV (P<0.010).

Conclusions: The significance for each lung function test is different among the stages of NSCLC. DLCO and 6MWT upon admission are the most valuable prognostic factors for overall survival of NSCLC.

Citing Articles

Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Salihi A, Al-Naqshabandi M, Khudhur Z, Housein Z, Hama H, Abdullah R Mol Med Rep. 2022; 26(1).

PMID: 35616143 PMC: 9178674. DOI: 10.3892/mmr.2022.12749.

Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer.

Cavalheri V, Burtin C, Formico V, Nonoyama M, Jenkins S, Spruit M Cochrane Database Syst Rev. 2019; 6:CD009955.

PMID: 31204439 PMC: 6571512. DOI: 10.1002/14651858.CD009955.pub3.

Exercise training for people following curative intent treatment for non-small cell lung cancer: a randomized controlled trial.

Cavalheri V, Jenkins S, Cecins N, Gain K, Phillips M, Sanders L Braz J Phys Ther. 2017; 21(1):58-68.

PMID: 28442076 PMC: 5537441. DOI: 10.1016/j.bjpt.2016.12.005.

A multifactoral analysis of 1452 patients for smoking sensation. An outpatient lab experience.

Tsiouda T, Zarogoulidis P, Petridis D, Pezirkianidis N, Kioumis I, Yarmus L J Cancer. 2014; 5(6):433-45.

PMID: 24847384 PMC: 4026997. DOI: 10.7150/jca.9360.

References

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

Barnett S, Rusch V, Zheng J, Park B, Rizk N, Plourde G . Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol. 2011; 6(9):1530-6. DOI: 10.1097/JTO.0b013e318228a0d8. View

Camus P, Fanton A, Bonniaud P, Camus C, Foucher P . Interstitial lung disease induced by drugs and radiation. Respiration. 2004; 71(4):301-26. DOI: 10.1159/000079633. View

Hole D, Watt G, Davey-Smith G, Hart C, Gillis C, Hawthorne V . Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996; 313(7059):711-5; discussion 715-6. PMC: 2352103. DOI: 10.1136/bmj.313.7059.711. View

Reif M, Socinski M, Rivera M . Evidence-based medicine in the treatment of non-small-cell lung cancer. Clin Chest Med. 2000; 21(1):107-20, ix. DOI: 10.1016/s0272-5231(05)70011-3. View

Camus P . Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer. 2004; 91 Suppl 2:S1-2. PMC: 2750812. DOI: 10.1038/sj.bjc.6602060. View

Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C . Guidelines on the radical management of patients with lung cancer. Thorax. 2010; 65 Suppl 3:iii1-27. DOI: 10.1136/thx.2010.145938. View

Win T, Groves A, Ritchie A, Wells F, Cafferty F, Laroche C . The effect of lung resection on pulmonary function and exercise capacity in lung cancer patients. Respir Care. 2007; 52(6):720-6. View

Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht M . Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest. 2004; 125(2):439-45. DOI: 10.1378/chest.125.2.439. View

10.

Jay S . Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1396. DOI: 10.1164/ajrccm.161.4.16147a. View

11.

Colice G, Shafazand S, Griffin J, Keenan R, Bolliger C . Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):161S-77S. DOI: 10.1378/chest.07-1359. View

12.

Calabro E, Randi G, La Vecchia C, Sverzellati N, Marchiano A, Villani M . Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J. 2009; 35(1):146-51. DOI: 10.1183/09031936.00049909. View

13.

Kasymjanova G, Correa J, Kreisman H, Dajczman E, Pepe C, Dobson S . Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol. 2009; 4(5):602-7. DOI: 10.1097/JTO.0b013e31819e77e8. View

14.

Jones L, Eves N, Kraus W, Potti A, Crawford J, Blumenthal J . The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer. 2010; 10:155. PMC: 2888787. DOI: 10.1186/1471-2407-10-155. View

15.

Bolliger C, Perruchoud A . Functional evaluation of the lung resection candidate. Eur Respir J. 1998; 11(1):198-212. DOI: 10.1183/09031936.98.11010198. View

16.

Liptay M, Basu S, Hoaglin M, Freedman N, Faber L, Warren W . Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol. 2009; 100(8):703-7. DOI: 10.1002/jso.21407. View

17.

Brundage M, Davies D, Mackillop W . Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122(3):1037-57. DOI: 10.1378/chest.122.3.1037. View

18.

Zarogoulidis K, Kontakiotis T, Hatziapostolou P, Fachantidou E, Delis D, Goutsikas J . A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer. 2001; 32(3):281-7. DOI: 10.1016/s0169-5002(00)00226-9. View

19.

Greene F, Sobin L . The TNM system: our language for cancer care. J Surg Oncol. 2002; 80(3):119-20. DOI: 10.1002/jso.10114. View

20.

Win T, Jackson A, Sharples L, Groves A, Wells F, Ritchie A . Relationship between pulmonary function and lung cancer surgical outcome. Eur Respir J. 2005; 25(4):594-9. DOI: 10.1183/09031936.05.00077504. View